X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (732) 732
Publication (82) 82
Book Chapter (7) 7
Book Review (3) 3
Conference Proceeding (2) 2
Magazine Article (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
simeprevir (517) 517
humans (512) 512
index medicus (490) 490
hepatitis c (341) 341
hepatitis c, chronic - drug therapy (331) 331
antiviral agents - therapeutic use (328) 328
ribavirin (319) 319
sofosbuvir (308) 308
hepatitis c virus (290) 290
male (281) 281
female (261) 261
drug therapy, combination (258) 258
middle aged (255) 255
gastroenterology & hepatology (247) 247
hepacivirus - genetics (239) 239
genotype (230) 230
treatment outcome (185) 185
interferon (181) 181
treatment-naive patients (179) 179
aged (177) 177
adult (160) 160
ribavirin - therapeutic use (158) 158
pegylated interferon (155) 155
simeprevir - therapeutic use (145) 145
hepacivirus - drug effects (142) 142
hepatitis (140) 140
hepatitis c - drug therapy (136) 136
telaprevir (136) 136
antiviral agents - administration & dosage (134) 134
antiviral agents (133) 133
antiviral agents - adverse effects (128) 128
daclatasvir (123) 123
hepatitis c, chronic - virology (118) 118
hcv (114) 114
pharmacology & pharmacy (113) 113
sustained virological response (113) 113
health aspects (112) 112
virus-infection (111) 111
therapy (110) 110
infection (108) 108
cirrhosis (106) 106
liver (104) 104
plus ribavirin (102) 102
ledipasvir (100) 100
genotype 1 infection (99) 99
infectious diseases (98) 98
sofosbuvir - therapeutic use (98) 98
double-blind (96) 96
genotype 1 (95) 95
liver cirrhosis (95) 95
care and treatment (94) 94
sulfonamides - therapeutic use (93) 93
biological response modifiers (91) 91
analysis (90) 90
liver transplantation (90) 90
protease inhibitors (88) 88
interferon-alpha - therapeutic use (85) 85
genetic aspects (84) 84
transplantation (83) 83
sustained virologic response (82) 82
drug therapy (80) 80
heterocyclic compounds, 3-ring - therapeutic use (80) 80
boceprevir (79) 79
ribavirin - administration & dosage (78) 78
simeprevir - administration & dosage (77) 77
direct-acting antivirals (75) 75
uridine monophosphate - analogs & derivatives (74) 74
hepatitis c, chronic - complications (73) 73
chronic hepatitis c (70) 70
simeprevir - adverse effects (64) 64
interferon-alpha 2a (63) 63
patients (63) 63
polyethylene glycols - therapeutic use (63) 63
retrospective studies (62) 62
genotype & phenotype (61) 61
infections (60) 60
recurrence (60) 60
sofosbuvir - administration & dosage (60) 60
virology (59) 59
virus diseases (59) 59
antiviral agents - pharmacology (58) 58
protease inhibitors - therapeutic use (57) 57
proteases (57) 57
gastroenterology and hepatology (56) 56
medicine, general & internal (56) 56
viral nonstructural proteins - antagonists & inhibitors (56) 56
young adult (56) 56
treatment-naive (55) 55
protease inhibitor (54) 54
recombinant proteins - therapeutic use (54) 54
safety (54) 54
hepatitis c - virology (53) 53
hepatology (53) 53
ribavirin - adverse effects (53) 53
peginterferon (52) 52
simeprevir plus sofosbuvir (52) 52
hepacivirus - isolation & purification (50) 50
uridine monophosphate - therapeutic use (50) 50
antiviral therapy (48) 48
hepacivirus (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (690) 690
German (10) 10
Russian (9) 9
Hungarian (8) 8
Japanese (7) 7
Korean (5) 5
Spanish (4) 4
Czech (3) 3
French (3) 3
Italian (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 06/2016, Volume 36, Issue 6, pp. 807 - 816
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 64, Issue 2, pp. 292 - 300
Journal Article
Hepatology, ISSN 0270-9139, 09/2015, Volume 62, Issue 3, pp. 715 - 725
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, pp. 1497 - 1504
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0158431
The prevalence of Hepatitis C Virus (HCV) infection is significantly higher in patients with end-stage renal disease compared to the general population and... 
RENAL-REPLACEMENT THERAPY | GENOTYPE 1 | SURVIVAL | IMPACT | METAANALYSIS | HIV | SOFOSBUVIR | MULTIDISCIPLINARY SCIENCES | DISEASE | SIMEPREVIR | HCV | Humans | Middle Aged | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Transplant Recipients | Simeprevir - adverse effects | Adult | Female | Retrospective Studies | Sofosbuvir - adverse effects | Drug Therapy, Combination | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Kidney Failure, Chronic - surgery | Antiviral Agents - therapeutic use | Liver Cirrhosis - complications | Ribavirin - therapeutic use | Treatment Outcome | Kidney Transplantation | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Kidney Failure, Chronic - complications | Aged | Antiviral agents | Complications and side effects | Care and treatment | Chronic kidney failure | Patient outcomes | Organ transplant recipients | Dosage and administration | Research | Health aspects | Therapy | End-stage renal disease | Nephrology | Transplants & implants | Hemodialysis | Calcineurin | Medical services | Calcineurin inhibitors | Chronic infection | Viruses | Transplantation | Infections | Ribavirin | Medical schools | Proteins | Hepatitis | Genotype & phenotype | Historical account | Hepatology | Surgery | Gastroenterology | Endoscopy | Drug dosages | Failure | Genotypes | Creatinine | Liver diseases | Kidneys | Mortality | Patients | Graft rejection | Cirrhosis | Side effects | Hospitals | Womens health | Fibrosis | Interferon | Kidney diseases | Hepatitis C virus | Hepatitis C | Kidney transplantation
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 5, pp. 1047 - 1055
Background & Aims Simeprevir (SMV) is a once-daily (QD), oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of genotype (GT) 1 and... 
Gastroenterology and Hepatology | Simeprevir | Chronic | Response-guided | Efficacy | Safety | TMC435 (10/10) | Hepatitis C virus | Sustained virologic response | Protease inhibitor | Genotype 4 | PLUS RIBAVIRIN | MONOTHERAPY | CHRONIC HEPATITIS-C | PHASE-3 | SUSTAINED VIROLOGICAL RESPONSE | THERAPY | PEGINTERFERON ALPHA-2B | DOUBLE-BLIND | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Hepatitis C, Chronic - ethnology | Secondary Prevention | Recombinant Proteins - adverse effects | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Hepacivirus - drug effects | Drug Administration Schedule | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Viral Load - drug effects | Viral Load - methods | Genetic aspects | Protease inhibitors | Hepatitis C | Proteases | Health aspects
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 04/2017, Volume 24, Issue 4, pp. 287 - 294
Journal Article
Liver Transplantation, ISSN 1527-6465, 04/2016, Volume 22, Issue 4, pp. 446 - 458
Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or... 
SURGERY | INTERFERON-ALPHA-2B | ANTIVIRAL THERAPY | RIBAVIRIN | COMBINATION | VIROLOGICAL RESPONSE | HCV INFECTION | TRANSPLANTATION | GENOTYPE 1 | PLUS SOFOSBUVIR | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | COMPASSIONATE USE | Recurrence | Liver Transplantation - adverse effects | Compassionate Use Trials | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Retrospective Studies | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Liver Cirrhosis - pathology | Liver Diseases - surgery | Aged | Infectious Medicine | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Infektionsmedicin
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, pp. CD012143 - CD012143
Journal Article